Angeles Investment Advisors LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,137 shares of the medical research company’s stock after buying an additional 80 shares during the quarter. Thermo Fisher Scientific makes up about 0.1% of Angeles Investment Advisors LLC’s investment portfolio, making the stock its 29th largest holding. Angeles Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,888,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in TMO. Morgan Stanley increased its holdings in shares of Thermo Fisher Scientific by 7.3% during the 1st quarter. Morgan Stanley now owns 8,293,242 shares of the medical research company’s stock valued at $3,784,871,000 after acquiring an additional 566,814 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 1.6% during the 1st quarter. Geode Capital Management LLC now owns 5,896,819 shares of the medical research company’s stock valued at $2,683,200,000 after acquiring an additional 93,794 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $2,336,640,000. JPMorgan Chase & Co. lifted its position in shares of Thermo Fisher Scientific by 1.2% during the 1st quarter. JPMorgan Chase & Co. now owns 4,560,676 shares of the medical research company’s stock worth $2,081,402,000 after purchasing an additional 53,508 shares during the last quarter. Finally, Primecap Management Co. CA lifted its position in shares of Thermo Fisher Scientific by 0.9% during the 1st quarter. Primecap Management Co. CA now owns 4,487,174 shares of the medical research company’s stock worth $2,047,856,000 after purchasing an additional 41,649 shares during the last quarter. Institutional investors and hedge funds own 85.90% of the company’s stock.
Shares of NYSE:TMO traded up $8.32 during mid-day trading on Thursday, reaching $522.58. The stock had a trading volume of 9,030 shares, compared to its average volume of 1,318,275. The company has a market cap of $205.39 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.22 and a beta of 0.76. The stock has a 50 day moving average of $483.14. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.91 and a current ratio of 2.53. Thermo Fisher Scientific Inc. has a twelve month low of $399.16 and a twelve month high of $532.57.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 15th. Investors of record on Wednesday, September 15th will be given a $0.26 dividend. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.20%. Thermo Fisher Scientific’s dividend payout ratio is 5.32%.
In related news, EVP Michel Lagarde sold 34,168 shares of the stock in a transaction that occurred on Friday, May 7th. The shares were sold at an average price of $472.60, for a total value of $16,147,796.80. Following the sale, the executive vice president now directly owns 52,629 shares in the company, valued at approximately $24,872,465.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.44% of the company’s stock.
TMO has been the subject of several research analyst reports. SVB Leerink reissued an “outperform” rating on shares of Thermo Fisher Scientific in a research report on Monday. The Goldman Sachs Group cut their price objective on Thermo Fisher Scientific from $590.00 to $530.00 and set a “buy” rating for the company in a research report on Tuesday, June 15th. They noted that the move was a valuation call. UBS Group decreased their price objective on Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a report on Monday, March 29th. Benchmark began coverage on Thermo Fisher Scientific in a report on Friday, July 16th. They set a “buy” rating and a $580.00 price objective on the stock. Finally, Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $545.00 to $550.00 and gave the company an “outperform” rating in a report on Wednesday, June 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $537.81.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Further Reading: What is a front-end load?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.